

(12) **United States Patent**
Bosch et al.(10) **Patent No.:** **US 6,656,504 B1**
(45) **Date of Patent:** **Dec. 2, 2003**(54) **NANOPARTICULATE COMPOSITIONS
COMPRISING AMORPHOUS
CYCLOSPORINE AND METHODS OF
MAKING AND USING SUCH
COMPOSITIONS**5,399,363 A 3/1995 Liversidge et al. 424/490
5,429,824 A 7/1995 June 424/489
5,439,686 A 8/1995 Desai 424/451

(List continued on next page.)


FOREIGN PATENT DOCUMENTS

(75) Inventors: **H. William Bosch**, Bryn Mawr, PA
(US); **Kevin D. Ostrander**, Reading,
PA (US); **Douglas C. Hovey**,
Collegeville, PA (US)EP 0 262 560 A2 9/1987
FR 2 608 427 6/1988
WO WO 96/14079 5/1996
WO WO 96/31202 10/1996
WO WO 97/35603 10/1997
WO 98/14174 4/1998(73) Assignee: **Elan Pharma International Ltd.**,
Shannon (IE)

OTHER PUBLICATIONS

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.Physicians Desk Reference "Neoral Sandimmune", 2000.*
Kondo et al., "Improved Oral Absorption of Enteric Copre-
cipitates of a Poorly Soluble Drug," *J. Pharm. Sciences*,
83(4):566-570 (1994).(21) Appl. No.: **09/392,557**Kondo et al., "Improved Oral Absorption of a Poorly
Water-Soluble Drug, HO-221, by Wet-Bead Milling Pro-
ducing Particles in Submicron Region," *Chem. Pharm.*
Bull., 41(4):737-740 (1993).(22) Filed: **Sep. 9, 1999**Kondo, et al., "Pharmacokinetics of a Micronized, Poorly
Water Soluble Drug, HO-221, in Experimental Animals,"
Biol. Pharm. Bull., 16(8):796-800 (1993).(51) **Int. Cl.**⁷ **A61K 9/14**; A61K 9/50;
A61K 38/00The Merck Index: An Encyclopedia of Chemicals, Drugs,
and Biologicals (12th Ed. 1996) pp. 464-465.(52) **U.S. Cl.** **424/489**; 424/501; 424/502;
514/11(58) **Field of Search** 424/489, 501,
424/502; 514/11, 937*Primary Examiner*—Thurman K. Page
Assistant Examiner—Amy E Pulliam
(74) *Attorney, Agent, or Firm*—Foley & Lardner(56) **References Cited**

U.S. PATENT DOCUMENTS

3,911,099 A * 10/1975 DeFoney et al.
4,540,602 A 9/1985 Motoyama et al. 427/213.31
4,727,077 A 2/1988 Haga et al. 514/274
4,783,484 A 11/1988 Violante et al. 514/535
4,826,689 A 5/1989 Violante et al. 424/489
4,851,421 A 7/1989 Iwasaki et al. 514/352
4,904,668 A 2/1990 Kondo et al. 514/274
4,983,605 A 1/1991 Kondo et al. 514/247
4,997,454 A 3/1991 Violante et al. 23/305 A
5,002,952 A 3/1991 Kondo et al. 514/274
5,098,907 A 3/1992 Kondo et al. 514/274
5,145,684 A 9/1992 Liversidge et al. 424/489
5,264,213 A 11/1993 Shibahara et al. 424/409
5,389,382 A * 2/1995 List et al.(57) **ABSTRACT**Nanoparticulate amorphous cyclosporine formulations, and
nanoparticulate cyclosporine formulations comprising a
mixture of amorphous and crystalline cyclosporine, having
effective average particle sizes of less than about 2000 nm
are described. The compositions exhibit increased bioavail-
ability and increased consistency of bioavailability as com-
pared to prior macro-sized cyclosporine and formulations.
Methods of making and using the compositions are also
described.**59 Claims, 3 Drawing Sheets**


U.S. PATENT DOCUMENTS

5,494,683 A	2/1996	Liversidge et al.	424/490	5,741,522 A	4/1998	Violante et al.	424/489
5,510,118 A *	4/1996	Bosch et al.	424/489	5,766,629 A *	6/1998	Cho et al.	424/455
5,518,187 A	5/1996	Bruno et al.	241/5	5,776,496 A	7/1998	Violante et al.	424/489
5,565,188 A	10/1996	Wong et al.	424/9.411	5,827,822 A *	10/1998	Floc'H et al.	514/11
5,587,143 A	12/1996	Wong	424/9.1	5,834,017 A *	11/1998	Cho et al.	424/455
5,622,938 A	4/1997	Wong	424/493	5,862,999 A	1/1999	Czekai et al.	241/21
5,718,388 A	2/1998	Czekai et al.	241/21	6,228,399 B1	5/2001	Parikh et al.	

* cited by examiner

FIG. 1

REPRESENTATIVE X-RAY POWDER DIFFRACTION
PATTERN OF CRYSTALLINE CYCLOSPORINE DRUG SUBSTANCE







FIG. 3

X-RAY POWDER DIFFRACTION PATTERN OF A MILLED CYCLOSPORINE FORMULATION HAVING HPC-SL AS A SURFACE STABILIZER.



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.